Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2005-11-24

Last Posted Date: 2013-04-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00258232

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: capecitabine
Drug: docetaxel

First Posted Date: 2005-11-24

Last Posted Date: 2014-03-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00258284

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2005-11-22

Last Posted Date: 2013-02-08

Lead Sponsor: University of California, Irvine

Target Recruit Count: 5

Registration Number: NCT00257348

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma

Phase 2

Terminated

Conditions: Gastric Carcinoma
Gastroesophageal Junction Carcinoma

Interventions: Drug: Oxaliplatin
Drug: Capecitabine
Drug: Celecoxib

First Posted Date: 2005-11-21

Last Posted Date: 2019-02-08

Lead Sponsor: University of California, Irvine

Target Recruit Count: 4

Registration Number: NCT00256321

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2005-11-15

Last Posted Date: 2013-04-08

Lead Sponsor: Herbert Hurwitz

Target Recruit Count: 25

Registration Number: NCT00253565

Locations: 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

First Posted Date: 2005-11-15

Last Posted Date: 2010-10-28

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 92

Registration Number: NCT00254137

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer

Phase 1

Completed

Conditions: Esophageal Cancer

First Posted Date: 2005-10-13

Last Posted Date: 2013-05-17

Lead Sponsor: University of Washington

Target Recruit Count: 18

Registration Number: NCT00238147

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated

Conditions: Breast Cancer

Interventions: Procedure: Biopsy
Procedure: Serum Collection
Procedure: Urine Collection
Drug: Gemcitabine
Drug: Doxorubicin
Drug: Capecitabine
Drug: Vinorelbine
Drug: Cyclophosphamide

First Posted Date: 2005-10-10

Last Posted Date: 2015-12-09

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 80

Registration Number: NCT00235235

Locations: 🇺🇸
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
🇺🇸
Baylor College of Medicine - Methodist Breast Center, Houston, Texas, United States
🇺🇸
Arnett Cancer Care, Lafayette, Indiana, United States

and more 8 locations

Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2005-09-30

Last Posted Date: 2015-04-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 15

Registration Number: NCT00230399

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Metastatic Cancer

Interventions: Biological: PEG-interferon alfa-2a
Drug: Capecitabine

First Posted Date: 2005-09-28

Last Posted Date: 2012-12-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00227656

Locations: 🇺🇸
University of Texas M.D. Anderson CCOP Research Base, Houston, Texas, United States
🇺🇸
CCOP - Grand Rapids, Grand Rapids, Michigan, United States
🇺🇸
Cancer Research for the Ozarks, Springfield, Missouri, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy